Pricing Log in Create free account
Friday 6 November 2026 Export SEPN’s income statement to Excel — free account

Septerna, Inc.

SEPN Healthcare Biotechnology

Septerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, up 4,174.5% from fiscal 2024.

Revenue
+22,375.6%
EPS
+48.2%
Free cash flow
−9.01%

Quarter to June 2026, against a year earlier

48.84 1.49 +3.15%
Market cap
$2.2B
P/E
0.0×
Fwd P/E
−32.6×
Dividend yield
—
F-score
5/9
Altman Z
3.41
Beneish M
32.85
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Septerna, Inc. (SEPN) Gross margin

Alert me on Gross margin

Septerna, Inc.'s gross margin over the twelve months to 30 June 2026 was 100.0%, down 0.0 percentage points from fiscal 2025 (100.0%). That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.

Gross margin, annual

Embed this chart

Annual newest first

Period Gross margin Change (points)
FY2025 100.0% 0.00
FY2024 100.0% 0.00
FY2023 100.0% —

Quarterly newest first

Period Gross margin Change (points)
Jun 2026 100.0% 0.00
Mar 2026 100.0% 0.00
Dec 2025 100.0% 0.00
Sep 2025 100.0% 0.00
7 more quarters

Gross margin against peers

Company Gross margin
IMNM Immunome, Inc. compare 100.0%
SEPN Septerna, Inc. 100.0%
PVLA Palvella Therapeutics, Inc. compare 100.0%
AUPH Aurinia Pharmaceuticals Inc compare 90.6%
LKFT Lakefront Biotherapeutics - Sponsored ADR compare 89.8%
VCEL Vericel Corporation compare 74.5%
VERA Vera Therapeutics, Inc. compare 0.00%
BHVN Biohaven Ltd. compare 0.00%
ZYME Zymeworks Inc. compare −246.7%
Biotechnology industry median 65.2%
Healthcare sector median 53.9%
Market median 45.1%

What Gross margin is

Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.

Gross Profit ÷ Revenue

The full definition of Gross margin →

More on SEPN